Related references
Note: Only part of the references are listed.A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Peter A. Riedell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
Boris Gorovits et al.
BIODRUGS (2019)
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
John K. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Maura C. O'Leary et al.
CLINICAL CANCER RESEARCH (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma
Richard T. Maziarz et al.
LEUKEMIA & LYMPHOMA (2018)
Costs of relapsed diffuse large B-cell lymphoma among Medicare patients
Scott Huntington et al.
LEUKEMIA & LYMPHOMA (2018)
Assessment of costs associated with adverse events in patients with cancer
William Wong et al.
PLOS ONE (2018)
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
Inmaculada Hernandez et al.
JAMA ONCOLOGY (2018)
Direct costs associated with adverse events of systemic therapies for advanced melanoma Systematic literature review
Catherine Copley-Merriman et al.
MEDICINE (2018)
Meeting Abstracts - Academy of Managed Care Pharmacy Nexus 2018
Journal of Managed Care & Specialty Pharmacy (2018)
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
E. Van den Neste et al.
BONE MARROW TRANSPLANTATION (2017)
Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia
Y. Liu et al.
DRUGS OF TODAY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E. Van den Neste et al.
BONE MARROW TRANSPLANTATION (2016)
Guidelines for the management of diffuse large B-cell lymphoma
Sridhar Chaganti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
Timothy S. Fenske et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011
Mohammed Al-Hamadani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
G. Mickisch et al.
BRITISH JOURNAL OF CANCER (2010)
Epidemiology of hematological malignancies
D. Rodriguez-Abreu et al.
ANNALS OF ONCOLOGY (2007)
Share Paper
